Long Yang

Long Yang inquired about the efficacy threshold Revolution Medicines is targeting for Diraxonrasib in first-line NSCLC and the combination potential of Diraxonrasib with Allieronrasib in first-line NSCLC.

Answer

Mark Goldsmith, Chairman and CEO, stated that the company does not provide pre-guidance on acceptable efficacy improvement thresholds, as it is a complex topic involving standard of care, statistical analysis, and regulatory discussions. Regarding the Diraxonrasib and Allieronrasib doublet, he reiterated the belief that combining a mutant-selective inhibitor with a RAS-on inhibitor offers the greatest impact, citing two clinical data sets (CRC and lung) that were directionally similar, but noted that prioritization among options is complex.

Long Yang asked about the efficacy threshold for Diraxonrasib in first-line NSCLC and commented on the combination potential of Diraxonrasib and Allieronrasib in first-line NSCLC.

Answer

Mark Goldsmith, Chairman and CEO, declined to provide specific efficacy guidance for first-line NSCLC, noting it is a complex topic for regulatory discussions. For the Diraxonrasib plus Allieronrasib doublet, he reiterated the belief that combining a mutant-selective inhibitor with a RAS-on inhibitor provides complementary benefits and maximal impact, citing two clinical data sets. He noted that prioritization is a complex matrix of considerations.